Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline

1. Richardson, P.G.
2. Sonneveld, P.
3. Schuster, M.W.
4. Stadtmauer, E.A.
5. Facon, T.
6. Harousseau, J.-L.
7. Ben-Yehuda, D.
8. Lonial, S.
9. Goldschmidt, H.
10. Reece, D.
11. Bladé, J.
12. Boccadoro, M.
13. Cavenagh, J.D.
14. Boral, A.L.
15. Esseltine, D.-L.
16. Wen, P.Y.
17. Amato, A.A.
18. Anderson, K.C.
19. San Miguel, J.